Provectus Biopharmaceuticals (PVCT) Receivables (2018 - 2024)
Provectus Biopharmaceuticals (PVCT) recorded Receivables of $340,050 in Q2 2024, down 69.4% from $1.11 million a year earlier and down 33.7% from the prior quarter.
Powered by 
Analysis
Provectus Biopharmaceuticals (PVCT) Receivables (2018 - 2024) Analysis & Trends
At the end of FY2023, Provectus Biopharmaceuticals reported Receivables of $777,275, down 34.2% from FY2022.
- Annual Receivables has a five-year compound annual growth rate of -8.2% (FY2018 to FY2023).
- Across earlier years, Receivables came in at $1.18 million in FY2022 (-58.7%), $2.86 million in FY2021, $7,860 in FY2020 (-92.9%) and $110,116 in FY2019 (-90.8%).
- The Q2 2024 figure is the lowest quarterly Receivables since Q3 2021.
- On a year-over-year basis, Receivables has declined for seven consecutive quarters, with an average decline of 46.4% over the last seven quarters.
- Peak year-over-year performance for Receivables in the last five years was growth of 43.2% in Q2 2021, against a decline of 98.7% in Q2 2020 at the low end.
- Per Business Quant, the preceding three quarters came in at $512,850 (Q1 2024), $777,275 (Q4 2023) and $1.16 million (Q3 2023).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,137.66 Bn | 1,106.24 Bn | 19.71 Bn | 23.48 Bn |
| 2 | Johnson & Johnson | 636.13 Bn | 556.00 Bn | 17.30 Bn | 18.99 Bn |
| 3 | AbbVie | 505.28 Bn | 478.39 Bn | 12.70 Bn | 13.82 Bn |
| 4 | Merck | 358.10 Bn | 312.48 Bn | 12.21 Bn | 12.56 Bn |
| 5 | Novartis Ag | 292.59 Bn | 256.58 Bn | 11.24 Bn | 9.64 Bn |
| 6 | Astrazeneca | 265.81 Bn | 239.50 Bn | 12.86 Bn | 15.68 Bn |
| 7 | Amgen | 237.53 Bn | 192.93 Bn | 7.24 Bn | 10.23 Bn |
| 8 | Gilead Sciences | 194.67 Bn | 168.86 Bn | 6.22 Bn | 5.06 Bn |
| 9 | Pfizer | 171.17 Bn | 117.82 Bn | 10.94 Bn | 12.49 Bn |
| 10 | Provectus Biopharmaceuticals | 21.01 Mn | 19.10 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2024 | 340,050.00 |
| Mar 31, 2024 | 512,850.00 |
| Dec 31, 2023 | 777,275.00 |
| Sep 30, 2023 | 1.16 Mn |
| Jun 30, 2023 | 1.11 Mn |
| Mar 31, 2023 | 1.07 Mn |
| Dec 31, 2022 | 1.18 Mn |
| Sep 30, 2022 | 1.46 Mn |
| Jun 30, 2022 | 1.79 Mn |
| Mar 31, 2022 | 2.23 Mn |
| Dec 31, 2021 | 2.86 Mn |
| Sep 30, 2021 | 2,708.00 |
| Jun 30, 2021 | 10,816.00 |
| Mar 31, 2021 | 8,776.00 |
| Dec 31, 2020 | 7,860.00 |
| Sep 30, 2020 | 11,860.00 |
| Jun 30, 2020 | 7,554.00 |
| Mar 31, 2020 | 148,470.00 |
| Dec 31, 2019 | 110,116.00 |
| Sep 30, 2019 | 572,188.00 |
API Access
Provectus Biopharmaceuticals Receivables API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=receivables&ticker=PVCT&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "receivables", "ticker": "PVCT", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=receivables&ticker=PVCT&period=max&api_key=YOUR_API_KEY");
const data = await res.json();